

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 March 2023 (09.03.2023)



(10) International Publication Number
WO 2023/034808 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07D 487/08 (2006.01)
C07D 401/12 (2006.01) A61K 31/4427 (2006.01)
C07D 401/14 (2006.01)

(21) International Application Number:

PCT/US2022/075678

(22) International Filing Date:

30 August 2022 (30.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/239,797 01 September 2021 (01.09.2021) US

(71) Applicant: THE UNITED STATES OF AMERICA,
AS REPRESENTED BY THE SECRETARY, DE-
PARTMENT OF HEALTH AND HUMAN SERVICES
[US/US]; 6701 Rockledge Drive, Suite 700, MSC 7788,
Bethesda, Maryland 20892-7788 (US).

(72) Inventors: BROGNARD, John F.; Center for Cancer Re-
search, NIH, LCDS, 8560 Progress Drive, Frederick, Mary-

land 21701 (US). SWENSON, Rolf E.; Imaging Probe
Development Center, NHLBI, 9800 Medical Center Drive,
Bldg B, #2034, Rockville, Maryland 20850 (US).
FUNK, Amy L.; National Cancer Institute, NIH, 9609
Medical Center Drive, Rockville, Maryland 20850 (US).
HITKO, Carolyn W.; Imaging Probe Development Center,
NHLBI, 9800 Medical Center Drive B-2022, Rockville,
Maryland 20850 (US). NYSWANER, Katherine M.; Center
for Cancer Research, NCI, LCDS, 8560 Progress Drive,
Frederick, Maryland 21701 (US). BERGMAN, Knick-
ole L.; BLDG 560, RM22-31, 1050 Boyles Street, Fred-
erick, Maryland 21702 (US). SABBASANI, Venkatar-
eddy; NHLBI/Chemistry and Synthesis Center, 9800 Med-
ical Center Drive, Rockville, Maryland 20850 (US). LIND-
BERG, Eric; NHLBI/Chemistry and Synthesis Center,
Building 2B, 9800 Medical Center Drive, Rockville, Mary-
land 20850 (US). CAPPELL, Steven D.; 37 Convent Drive,
Building 37, Room 4054C, Bethesda, Maryland 20892
(US). KATERJI, Meghri; FDC 560 BG RM 12-34, 560
Chandler Street, Frederick, MD 21702 (US).

(54) Title: MIXED LINEAGE KINASE INHIBITORS AND METHODS OF USE





FIG. 50



(57) Abstract: Mixed lineage kinase (MLK) inhibitors are disclosed. The compounds inhibit kinase activity. The compounds may be used to treat diseases or conditions characterized at least in part by overexpression of one or more MLKs. The compounds have a structure according to formula I, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

[Continued on next page]

(74) **Agent: GARDNER, Gillian** et al.; Klarquist, One World Trade Center, Suite 1600, 121 SW Salmon Street, Portland, Oregon 97204 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*